Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR-1707 in Healthy Young and Elderly Subjects
NCT04745104Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1707 in Alzheimer's disease (AD) (6 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Adverse events at 12 weeks. Started Feb 2021; status: completed.
02
Drugs
SHR-1707
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04745104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745104.